Efalizumab

In the US, Efalizumab (efalizumab systemic) is a member of the drug class selective immunosuppressants and is used to treat Psoriasis.

US matches:

• Efalizumab


• Efalizumab Subcutaneous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA21

CAS registry number (Chemical Abstracts Service)

0214745-43-4

Therapeutic Category

Selective immunosuppressant

Chemical Name

Immunoglobulin G1, anti - (human antigen CD 11a) (human-mouse monoclonal hu 1124 gamma 1 - chain), disulfide with human-mouse monoclonal hu 1124 light chain, dimer (WHO)

Foreign Names

• Efalizumabum (Latin)
• Efalizumab (German)
• Efalizumab (French)
• Efalizumab (Spanish)

Generic Names

• Efalizumab (OS: USAN)
• anti - CD 11a (IS)
• anti - CD 11a MAb (IS)
• hu 1124 (IS)
• Humanized MHM 24 (IS)

Brand Names

• Raptiva
  EMD Serono, Canada; Genentech, Bulgaria; Genentech, United States; Merck, Croatia (Hrvatska); Merck Serono, Australia; Merck Serono, Denmark; Serono, Argentina; Serono, Brazil; Serono, Hong Kong; Serono, Israel; Serono, Iceland; Serono, Norway; Serono, Oman; Serono, Serbia; Serono, Singapore; Serono, Slovenia; Serono, Turkey

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.